Cargando…

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing

For many years, the risk-based therapy stratification of children with neuroblastoma has relied on clinical and molecular covariates. In recent years, genome analysis has revealed further alterations defining risk, tumor biology, and therapeutic targets. The implementation of a robust and scalable m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szymansky, Annabell, Kruetzfeldt, Louisa-Marie, Heukamp, Lukas C., Hertwig, Falk, Theissen, Jessica, Deubzer, Hedwig E., Willing, Eva-Maria, Menon, Roopika, Fuchs, Steffen, Thole, Theresa, Schulte, Stefanie, Schmelz, Karin, Künkele, Annette, Lang, Peter, Fuchs, Jörg, Eggert, Angelika, Eckert, Cornelia, Fischer, Matthias, Henssen, Anton G., Rodriguez-Fos, Elias, Schulte, Johannes H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398598/ https://www.ncbi.nlm.nih.gov/pubmed/34442335 http://dx.doi.org/10.3390/jpm11080691

Ejemplares similares

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
por: Fuchs, Steffen, et al.
Publicado: (2023)

Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions
por: Schmelz, Karin, et al.
Publicado: (2021)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017)

Mutational topography reflects clinical neuroblastoma heterogeneity
por: Rodriguez-Fos, Elias, et al.
Publicado: (2023)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017)

Targeting tachykinin receptors in neuroblastoma
por: Henssen, Anton G., et al.
Publicado: (2016)

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016)

Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics
por: Lodrini, Marco, et al.
Publicado: (2022)

Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
por: Helmsauer, Konstantin, et al.
Publicado: (2020)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
por: Thole, Theresa M, et al.
Publicado: (2017)

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022)

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4(+) CAR T Cell Efficacy
por: Ali, Solin, et al.
Publicado: (2020)

Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
por: Wu, Zhiyang, et al.
Publicado: (2021)

Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry
por: Jazmati, Danny, et al.
Publicado: (2022)

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
por: Grunewald, Laura, et al.
Publicado: (2021)

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2017)

Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
por: Timme, Natalie, et al.
Publicado: (2019)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis
por: Sulejmani, Ornela, et al.
Publicado: (2021)

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
por: Künkele, Annette, et al.
Publicado: (2013)

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016)

Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells
por: Chamorro González, Rocío, et al.
Publicado: (2023)

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance
por: Dorel, Mathurin, et al.
Publicado: (2021)

Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion
por: Thorwarth, Anne, et al.
Publicado: (2022)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
por: Arlt, Birte, et al.
Publicado: (2021)

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
por: Pajtler, Kristian W, et al.
Publicado: (2013)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines
por: Klenke, Stefanie, et al.
Publicado: (2019)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform
por: Wu, Dongwei, et al.
Publicado: (2021)

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2013)

The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse
por: Riehl, Lara M., et al.
Publicado: (2015)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
por: Textor, Ana, et al.
Publicado: (2021)

Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry
por: Jazmati, Danny, et al.
Publicado: (2021)

Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells
por: Pajtler, Kristian W., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_op8n54el9d96pvcauhjc469ttk